Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy

Clinical Lymphoma and Myeloma

Volumn 6, Issue 4, 2006, Pages 329-332

  Berthelot, Cindy ^a   Cather, Jennifer ^b   Jones, Dan ^c   Duvic, Madeleine ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Baylor Medicine Center   (United States)

^c University of Texas Health Science Center at Houston   (United States)

Author keywords

Efalizumab; Infliximab; Mycosis fungoides; Sezary syndrome

Indexed keywords

BEXAROTENE; CHLORAMBUCIL; CHLORMETHINE; COTRIMOXAZOLE; DOXORUBICIN; EFALIZUMAB; ETOPOSIDE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISONE; PROCARBAZINE; PSORALEN; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; VINBLASTINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ANAMNESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CHRONIC DIARRHEA; CLINICAL FEATURE; COLON BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; DERMATOMYCOSIS; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOSIS FUNGOIDES; PSORIASIS; PUVA; RHEUMATOID ARTHRITIS; SEZARY SYNDROME; SKIN BIOPSY; STAPHYLOCOCCUS INFECTION; TREATMENT WITHDRAWAL; ULTRAVIOLET IRRADIATION; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; T CELL LYMPHOMA;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PSORIASIS; SKIN NEOPLASMS;

EID: 33645095736     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.008     Document Type: Article

References (24)

1. Mahe E, Descamps V, Grossin M, et al. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003; 149:170-173.
2. Fardet L, Blanche S, Brousse N, et al. Cutaneous EBV-related lymphoproliferative disorder in a 15-year-old boy with AIDS: an unusual clinical presentation. J Pediatr Hematol Oncol 2002: 24:666-669.
3. Ward HA, Russo GG, McBurney E, et al. Post-transplant primary cutaneous T-cell lymphoma. J Am Acad Dermatol 2001; 44:675-680.
4. Hohaus S, Di Febo, A, Storti S, et al. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkins lymphoma. Haematologica 2004; 89:751-752.
5. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50:1740-1751.
6. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46:3151-3158.
7. Amevive® [package insert]. Biogen Idec; 2003. Available at: www.amevive.com. Accessed February 10, 2005.
8. Humira® [package insert]. Abbott Park, IL: Abbott Laboratories; 2004 Available at www.humira.com. Accessed February 11, 2005.
9. U.S. Food and Drug Administration. Available at: www.fda.gov/ohrms/dockets/ac/03/slides/ 3983S1_02_e-genentech-safety.ppt-O9-23-2003. Accessed April 5, 2005.
10. Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol 2002; 47:914-918.
11. Baecklund E, Askling J, Rosenquist R, et al. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004; 16:254-261.
12. Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion [published erratum in Blood 1997; 89:3496]. Blood 1997; 89:32-40.
13. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25:2487-2505.
14. Wendling D, Toussirot E. Anti-TNF-alpha therapy in ankylosing spondylitis. Expert Opin Pharmacother 2004; 5:1497-1507.
15. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 2004; 15:280-294.
16. Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther 2004; 6:S12-S18.
17. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64:1414-1420.
18. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34:819-836.
19. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64:699-703.
20. Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol 2004; 51:660-662.
21. Symmons DP, Silman AJ. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum 2004; 50:1703-1706.
22. Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48:963-970.
23. van Hogezand RA, Eichhorn RF, Choudry A, et al. Malignancies in inflammatory bowel disease: fact or fiction? Scand J Gastroenterol Suppl 2002; 236:48-53.
24. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and inummosuppressive treatment. Aliment Pharmacol Ther 2001; 15:1101-1108.